MetaVia (NASDAQ:MTVA) Releases Earnings Results, Beats Estimates By $0.04 EPS

MetaVia (NASDAQ:MTVA) announced its quarterly earnings results on Friday. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04, FiscalAI reports.

MetaVia Stock Performance

MTVA remained flat at $1.30 on Friday. The company had a trading volume of 49,372 shares, compared to its average volume of 193,040. The firm has a market cap of $6.71 million, a P/E ratio of -0.40 and a beta of 1.24. MetaVia has a 12 month low of $0.97 and a 12 month high of $13.42. The company’s 50-day moving average is $1.46 and its two-hundred day moving average is $1.61.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research report on Monday, October 19th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.00.

MetaVia Company Profile

MetaVia, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction. The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.